PRIMARY PERITONEAL CANCER

This study tests a new drug called BL-B01D1 against standard chemotherapy in 384 adults with ovarian, fallopian tube, or primary peritoneal cancer that has become resistant to platinum-based treatment. The goal is to see if BL-B01D1 can slow cancer growth and improve survival. Pa…

This early-phase study is testing whether combining two drugs, Cirtuvivint and Olaparib, is safe for people with ovarian cancer that no longer responds to platinum chemotherapy. About 50 women with specific genetic markers (BRCA/HRD) will take the pills at different schedules. Th…

This study tests a new drug called TORL-1-23 given with chemotherapy before surgery for women with advanced ovarian cancer. The goal is to see if the combination is safe and helps shrink tumors more effectively. About 60 women with stage III or IV ovarian, fallopian tube, or peri…

This study tests an experimental drug called ART0380, taken as a pill, for people with advanced or metastatic solid tumors (cancers that have spread). The goal is to find a safe dose and see if it works alone or with standard chemotherapies (gemcitabine or irinotecan). About 442 …

This study tests whether a new drug combination (sacituzumab tirumotecan with or without bevacizumab) can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer getting worse. About 770 adults whose cancer responded to second-line chemothera…

This study tests whether adding an experimental drug (IMNN-001) to standard chemotherapy and bevacizumab can better eliminate tiny leftover cancer in people with newly diagnosed advanced ovarian, fallopian tube, or peritoneal cancer. About 30 participants will be randomly assigne…

This study tests an investigational drug called REGN5668, alone or combined with other drugs, in people with ovarian, fallopian tube, primary peritoneal, or endometrial cancers. The goal is to find the safest dose and see if the treatment can shrink tumors. About 612 participants…

This study tests a new drug combination (carboplatin and mirvetuximab) as the first treatment for people with advanced ovarian, fallopian tube, or peritoneal cancer that has a specific marker (folate receptor alpha). About 70 participants will receive the drugs before and after s…

This study tests whether a combination of two drugs (a PARP inhibitor and an angiogenesis inhibitor) can help keep advanced ovarian, fallopian-tube, or primary peritoneal cancer from coming back after initial treatment. About 120 adults with a specific genetic feature (HRD) will …

This study tests whether adding a vitamin A-like drug (ATRA) to a platelet-boosting medication (romiplostim N01) works better than the platelet drug alone for cancer survivors whose platelet counts stay low after chemotherapy. About 220 adults with gynecologic, breast, or lung ca…

This study tests whether a cancer-killing virus (Olvi-Vec) given into the abdomen can make platinum-resistant ovarian cancer respond to chemotherapy again. About 186 women whose cancer has not responded to at least three prior treatments will receive either Olvi-Vec plus chemo an…

This study tests a new drug combination (carboplatin plus mirvetuximab soravtansine) given before surgery to people with advanced ovarian, fallopian tube, or peritoneal cancer that has a specific protein (FRα). The goal is to see if the treatment shrinks tumors enough to improve …

This study tests a new oral drug, AVZO-021, in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called CDK2 to slow or stop cancer growth. The trial has two phases: first to find the safest dose, then to see if it shrinks t…

This study tests an experimental drug called ubamatamab, alone or with other cancer drugs, in people with advanced ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see how safe and effective these combinations are. About 220 participants w…

This study tests a telehealth program called REVITALIZE to see if it can lessen how much fatigue interferes with daily life for people with advanced ovarian cancer who are taking PARP inhibitors. About 240 adults will be randomly assigned to either the REVITALIZE program or recei…

This study follows 1,000 women with newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer to see how their genetic makeup (BRCA and HRD status) influences their response to standard treatments. Participants receive usual care, and researchers collect data on surge…